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Abstract
Background: Particulate systems are well known to be able to deliver drugs with high efficiency
and fewer adverse side effects, possibly by endocytosis of the drug carriers. On the other hand,
cationic compounds and assemblies exhibit a general antimicrobial action. In this work, cationic
nanoparticles built from drug, cationic lipid and polyelectrolytes are shown to be excellent and
active carriers of amphotericin B against C. albicans.
Results: Assemblies of amphotericin B and cationic lipid at extreme drug to lipid molar ratios were
wrapped by polyelectrolytes forming cationic nanoparticles of high colloid stability and fungicidal
activity against Candida albicans. Experimental strategy involved dynamic light scattering for particle
sizing, zeta-potential analysis, colloid stability, determination of AmB aggregation state by optical
spectra and determination of activity against Candida albicans in vitro from cfu countings.
Conclusion: Novel and effective cationic particles delivered amphotericin B to C. albicans in vitro
with optimal efficiency seldom achieved from drug, cationic lipid or cationic polyelectrolyte in
separate. The multiple assembly of antibiotic, cationic lipid and cationic polyelctrolyte,
consecutively nanostructured in each particle produced a strategical and effective attack against the
fungus cells.
Background
In the recent years, much work has been devoted to char-
acterize nanoparticles and their biological effects and
applications. These include bottom-up and molecular
self-assembly, biological effects of naked nanoparticles
and nano-safety, drug encapsulation and nanotherapeu-
tics, and novel nanoparticles for use in microscopy, imag-
ing and diagnostics [1]. Particulate drug delivery systems
such as polymeric microspheres [2], nanoparticles [3,4],
liposomes [5,6], and solid lipid nanoparticles (SLNs) [7]
offer great promise to achieve the goal of improving drug
accumulation inside cancer cells without causing side
effects. Particulate systems are well known to be able to
deliver drugs with higher efficiency with fewer adverse
side effects [6,8]. A possible mechanism is increase of cel-
lular drug uptake by endocytosis of the drug carriers [9-
11]. The emergence of the newer forms of SLN such as pol-
ymer-lipid hybrid nanoparticles, nanostructured lipid car-
riers and long-circulating SLN may further expand the role
of this versatile drug carrier aiming at chemotherapy with
cancer drugs [12]. Recently, new nanoparticulate delivery
systems for amphotericin B (AmB) have been developed
by means of the polyelectrolyte complexation technique
[13,14]. Two oppositelly charged polymers were used to
form nanoparticles through electrostatic interaction as
usual for the Layer-by-Layer approach (LbL). This
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approach creates homogeneous ultrathin films on solid
supports based on the electrostatic attraction between
opposite charges [15]. Consecutively alternating adsorp-
tion of anionic and cationic polyelectrolytes or
amphiphiles from their aqueous solution leads to the for-
mation of multilayer assemblies [16].
On the other hand, some double-chained synthetic lipids
such as dioctadecyldimethylammonium bromide
(DODAB) or sodium dihexadecylphosphate (DHP) self-
assemble in aqueous solution yielding closed bilayers
(vesicles) or disrupted vesicles (bilayer fragments, BF, or
disks) depending on the procedure used for dispersing the
lipid [17]. DODAB, in particular, bears a quaternary
ammonium moiety as cationic polar head, which imparts
to this cationic lipid outstanding anti-infective properties
[18]. Both amphotericin B and miconazole self-assemble
and solubilize at hydrophobic sites of DODAB or DHP
bilayer fragments in water solution exhibiting in vivo ther-
apeutic activity [19-22]. Over the last decade, our group
has been describing the anti-infective properties of cati-
onic bilayers composed of the synthetic lipid dioctade-
cyldimethyl ammonium bromide (DODAB) [17,18,21-
27]. Adsorption of DODAB cationic bilayers onto bacte-
rial cells changes the sign of the cell surface potential from
negative to positive with a clear relationship between pos-
itive charge on bacterial cells and cell death [26]. Regard-
ing the mechanism of DODAB action, neither bacterial
cell lysis nor DODAB vesicle disruption takes place [27].
Recently, it was shown that the critical phenomenon
determining antifungal effect of cationic surfactants and
lipids is not cell lysis but rather the reversal of cell surface
charge from negative to positive [28]. In this work, we
combine the SLN and the LbL approaches to develop
novel and effective cationic particles to deliver AmB to C.
albicans. Cationic microbicides self-assemble in a single
supramolecular structure. The first attack against the fun-
gus comes from an outer cationic polyelectrolyte layer.
Thereafter the inert carboxymethylcellulose (CMC) layer
is unwrapped so that monomeric AmB solubilized at the
edges of DODAB bilayer fragments (BF) and the BF them-
selves can contact the fungus cell. Maybe this design rep-
resents a very effective cocktail against multidrug
resistance. Complete loss of fungus viability could not be
achieved before at the same separate doses of each com-
ponent.
Results and Discussion
Colloid stability and antifungal activity of cationic bilayer 
fragments/amphotericin B/carboxymethyl cellulose/
poly(diallyldimethylammonium) chloride at low drug-to-
lipid molar proportion
Chemical structures of amphotericin B (AmB), car-
boxymethylcellulose (CMC), poly(diallyldimethylammo-
nium chloride) (PDDA) and the cationic lipid
dioctadecyldimethylammonium bromide (DODAB) are
on Table 1. DODAB self-assembly in water dispersion
yields bilayer fragments (BF) by ultrasonic input with a
macrotip probe.
The existence of bilayer fragments from synthetic lipids
such as sodium dihexadecylphosphate, or dioctadecyld-
imethylammonium bromide or chloride obtained by son-
ication with tip has been supported by the following
evidences: (i) osmotic non-responsiveness of the disper-
sion indicative of absence of inner vesicle compartment
[29]; (ii) TEM micrographs with electronic staining [30];
(iii) cryo-TEM micrographs [31]; (iv) fluid and solid state
coexistence and complex formation with oppositely
charged surfactant [32]; (v) solubilization of hydrophobic
drugs at the borders of DODAB bilayer fragments, which
does not occur for DODAB closed bilayer vesicles [19-
Table 1: Sizing and zeta-potential of drug, cationic lipid and anionic polyelectrolyte in separate or as assemblies
Dispersion [DODAB] (mM) [AmB] (mM) [CMC] (mg/mL) D ± δ (nm) ζ ± δ (mV)
AmB in water --- 0.005 --- 433 ± 5 -26 ± 3
DODAB BF 1 - - - --- 79 ± 2 41 ± 2
DODAB BF/AmB 1 0.005 --- 79 ± 1 42 ± 2
DODAB BF/AnB/CMC 1 0.005 0.01 88 ± 1 40 ± 1
1 0.005 0.1 145 ± 1 32 ± 2
1 0.005 1 90 ± 2 -50 ± 2
AmB in water --- 0.050 --- 360 ± 4 -26 ± 3
AmB in IGP --- 0.050 --- 75 ± 2 -27 ± 1
DODAB BF in IGP 0.1 - - - --- 75 ± 1 40 ± 1
AmB/DODAB BF 0.1 0.050 --- 195 ± 3 9 ± 1
AmB/DODAB BF/CMC 0.1 0.050 0.001 199 ± 1 16 ± 1
0.1 0.050 0.01 1280 ± 80 4 ± 1
0.1 0.050 0.1 230 ± 2 -34 ± 1
Zeta-average diameter (D) and zeta-potentials (ζ) for different dispersions aiming at formulation of AmB in cationic lipid DODAB and CMC. 
Dispersions were prepared either in Milli-Q water or in IGP buffer.Journal of Nanobiotechnology 2008, 6:6 http://www.jnanobiotechnology.com/content/6/1/6
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21,33,34]. They differ from the closed vesicles by provid-
ing hydrophobic borders at their edges that are absent in
closed bilayer systems such as vesicles or liposomes.
Under conditions of low ionic strength, due to electro-
static repulsion, the charged bilayer fragments remain col-
loidally stable in aqueous dispersions [19-21,33,34].
In fact, DODAB BF have been used to solubilize AmB [19]
at room temperature as schematically shown in Figure 1.
This solubilization takes place at low drug-to-lipid molar
proportions (low P) and presents certain limitations: 1)
hydrophobic edges of bilayer fragments have a limited
capacity of solubilizing the hydrophobic drug; 2) the
bilayer core in the rigid gel state is too rigid to allow solu-
bilization of AmB at room temperature being a poor sol-
ubilizer for this difficult, hydrophobic drug
[19,20,33,35]. On the other hand, at high P, AmB aggre-
gates in water solution can be considered as drug particles.
These can be surrounded by a thin cationic DODAB
bilayer as previously described [35] (Figure 1).
The physical properties of different dispersions such as
size and zeta-potential are given in Table 1 both at low
and high P. The drug in water exhibits substancial aggre-
gation (Dz = 360–433 nm), as expected from its hydro-
phobic character. The drug particle presents a negative
zeta-potential of -26 mV explained by dissociation of its
carboxylate moiety at the pH of water [35]. Upon chang-
ing the medium to IGP buffer, as previously reported, a
decrease in size for AmB aggregates was observed (Dz = 75
nm) (Table 1), due to the chaotropic (dispersing) effect of
dihydrogenphosphate anion on AmB aggregates [35].
Both types of AmB aggregates interacted with DODAB BF
yielding either loaded BF fragments at low P or DODAB
covered drug particles at high P. The characteristics of
these cationic assemblies before and after their interaction
with oppositely charged CMC over a range of concentra-
tions (0.001–1.0 mg/mL) are in Table 1. At low P, charge
reversal took place above 1 mg/mL CMC whereas at high
P, it occurred above 0.1 mg/mL CMC (Table 1).
At low P, the effect of CMC concentration on DODAB BF/
CMC (unloaded control) or DODAB BF/AmB/CMC prop-
erties is in Figure 2. At low P and 1 mg/mL CMC, DODAB
BF/AmB/CMC anionic complexes present 90 nm mean
diameter and -50 mV of zeta-potential. The low size and
large surface potential mean high colloid stability, so that
this was the condition chosen for coverage with cationic
polyelectrolytes. In the presence of CMC, there are two
regions of colloid stability for cationic or anionic assem-
blies characterized by small sizes: regions I and III, and
one region of instability: region II, characterized by aggre-
gation and large sizes (Figure 1). Charged particles cov-
ered by oppositely charged polyelectrolytes exhibited
similar profiles for the colloid stability as a function of
polyelectrolyte concentration [36,37].
The aggregation state of AmB at low P was evaluated from
optical spectra (Figure 3). The drug in DMSO:methanol
1:1 yields a spectrum of completely solubilized, nonaggre-
gated drug since this organic solvent mixture is the one of
choice for AmB solubilization (Figure 3A). The drug in
water exhibits the typical spectrum of aggregated AmB
(Figure 3B). As depicted from AmB spectrum in DODAB
BF (Figure 3C) or DODAB BF/AmB/CMC (Figure 3D), the
drug is found in its monomeric state and completely sol-
ubilized. In fact, solubilization of AmB in DODAB BF, at
low P, was previously described [19]. This formulation
employing DODAB BF at low P was very effective in vivo
[21] and exhibited low nephrotoxicity [22].
At low P, the effect of [PDDA] on sizes and zeta-potentials
of DODAB BF/AmB/CMC assemblies at 1 mM DODAB,
0.005 mM AmB and 1 mg/mL CMC is on Figure 4. The
region of PDDA concentrations for size minimization and
high colloid stability was very narrow and around 1 mg/
mL PDDA. Below and above this concentration, about
300 nm and negative zeta-potentials, or 500–700 nm of
zeta-average diameter and positive zeta-potentials were
obtained, respectively (Figure 4). Size minimization at Dz
= 171 nm and zeta-potential = 24 mV for the DODAB BF/
AmB/CMC/PDDA assembly was not related to optimal
fungicidal activity as depicted from the 79% of C. albicans
viability (Table 2). Possibly, the total positive charge on
the assembly was not sufficient to substantially reduce
fungus viability. For final coverage with polylysines (PL)
of increasing molecular weight at 1 mg/mL PL, there was
an increase in the final zeta-potential modulus and a
larger loss of viability (Table 2). The DODAB BF/AmB/
CMC/PDDA formulation at low P was 100% effective
against the fungus only at 5 mg/mL PDDA (Figure 5D).
The importance of large positive zeta-potentials for high
efficiency of drug assemblies with DODAB BF and polye-
lectrolytes can be clearly seen from Figure 5. Negatively
charged assemblies like those in Figure 5A and 5B yielded
100% of cell viability. Positively charged assemblies
obtained upon increasing [PDDA] reduced cell viability to
50% (CMC/PDDA) (Figure 5C) or to 0% (DODAB BF/
AmB/CMC/PDDA above 5 mg/mL PDDA) (Figure 5D).
The schematic drawing in Figure 5D illustrates the layered
assembly of microbicides in a single supramolecular
assembly. The first attack comes from the outer cationic
polyelectrolyte layer. Upon unwrapping this first layer
and the second inert CMC layer, monomeric AmB con-
tacts the fungus cell followed by the also effective DODAB
action. Maybe this design represents a very effective
assembly against multidrug resistance. Complete loss ofJournal of Nanobiotechnology 2008, 6:6 http://www.jnanobiotechnology.com/content/6/1/6
Page 4 of 13
(page number not for citation purposes)
Chemical structure or schematic assemblies of compounds used to formulate amphotericin B Figure 1
Chemical structure or schematic assemblies of compounds used to formulate amphotericin B. Each molecule of 
amphotericin B that was solubilized at the edges of DODAB bilayer fragments was represented by an ellipsoid whereas aggre-
gated drug forming a particle was represented by solid spheres.
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fungus viability can seldom be achieved at the same sepa-
rate doses of each component [25].
Colloid stability and antifungal activity of AmB/DODAB 
BF/CMC/PDDA at high P
The complexation between DODAB BF and CMC was pre-
viously studied in detail by our group [36]. DODAB BF at
0.1 mM DODAB and CMC (0.001–2 mg/mL) are, in fact,
electrostatically driven to complexation from the electro-
static attraction (Figure 6A and 6B).
At high P, 0.1 mM DODAB BF is sufficient to cover all
AmB particles present in dispersion at 0.05 mM AmB with
a thin, possibly bilayered, 6–8 nm DODAB cationic shell
as previously described [35]. This cationic interface is
expected to interact with the oppositely charged CMC pol-
yelectrolyte. At 0.1 mg/mL CMC, AmB/DODAB BF/CMC
anionic complexes present high colloid stability, 230 nm
mean diameter and -34 mV of zeta-potential (Figure 6C
and 6D). This condition was chosen for further coverage
with cationic polylectrolytes.
Regarding the aggregation state of AmB, as expected, at
0.05 mM AmB, the majority of drug molecules were
found in the aggregated state. Spectra in IGP buffer (Figure
7A), after drug particle coverage with 0.1 mM DODAB BF
(Figure 7B) or with 0.1 mM DODAB BF plus 0.1 mg/mL
CMC (Figure 7C) revealed the typical profile of aggregated
drug. The spectrum in Figure 7C indicates a certain
amount of monomeric drug not present in the other spec-
tra (Figure 7A and 7B). Possibly, CMC sterically stabilized
DODAB BF preserving hydrophobic sites of DODAB BF to
be occupied by the monomeric drug. In absence of CMC,
DODAB BF might fuse diminishing drug solubilization at
their rim.
Amphotericin B solubilized in cationic bilayer fragments adsorbs a layer of carboxymethyl cellulose Figure 2
Amphotericin B solubilized in cationic bilayer fragments adsorbs a layer of carboxymethyl cellulose. Effect of 
CMC concentration on zeta-average diameter (A, C) and zeta-potential (B, D) of unloaded DODAB BF (A, B) or DODAB BF/
AmB (C, D) at low drug-to-lipid molar proportion. Final DODAB and/or AmB concentrations are 1 and 0.005 mM, respec-
tively. The three different moieties of the curves were named I, II and III corresponding to positive, zero and negative zeta-
potentials, respectively.
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At the chosen condition for the AmB/DODAB BF/CMC
assembly, the effect of increasing [PDDA] was an initial
colloid stabilization (decrease in size) around 1 mg/mL
PDDA followed by further destabilization (increase in
size) above this concentration (Figure 8A), possibly due to
bridging flocculation [38]. Zeta-potential displayed the
usual sigmoidal dependence on [PDDA] (Figure 8B).
The importance of positively charged assemblies at high P
for fungicidal activity is emphasized in Figure 9. C. albi-
cans remains 100% viable in the presence of negatively
charged CMC only (Figure 9A), 70% viable in the pres-
ence of negatively charged AmB/DODAB BF/CMC at high
P (Figure 9B), 50–60% viable in the presence of CMC/
PDDA at [PDDA] > 1 mg/mL and 0% viable in the pres-
ence of AmB/DODAB BF/CMC/PDDA at PDDA ≥ 2 mg/
mL (Figure 9D).
Alternatively, PDDA was replaced by PL (Table 2). At high
P, the effect of increasing PL molecular weight was an
increase in size, an increase in zeta-potential and a
decrease of % of cell viability (Table 2). Table 1 summa-
rized the different properties of assemblies at low and
high P. One should notice that coverage of a drug particle
with a thin DODAB layer led to a positive zeta-potential
of only 9 mV. CMC was slightly attracted to the covered
particle producing a looser assembly than the one
obtained with CMC coverage of DODAB BF, where elec-
trostatic attraction is due to a higher zeta-potential on the
bilayer fragments, typically 41 mV. The particles are
loosely or tightly packed depending on the electrostatic
attraction between oppositely charged components (cati-
onic layer and CMC) depicted from zeta-potentials. This
certainly made a large difference for occasion of drug
delivery to the fungus cell. Having a loose or a more
tightly packed assembly originated considerable differ-
ences in the profile of cell viability as a function of zeta-
potential (Figure 10). For the less tightly packed drug par-
ticles at high P, drug delivery was more efficient leading to
drug release and cell death at lower zeta-potentials (Figure
10). The reason for this high efficiency at low zeta-poten-
tial is associated both with the high P, meaning high drug
dose, and with the loosely packed nanoparticle assembly.
Fungizon (AmB in deoxycholate) and DODAB BF/AmB
(formulation at low P) were previously evaluated in mice
with systemic candidiasis [21]. Both formulations yielded
equivalent therapeutic results. However, DODAB BF/AmB
was better from the point of view of reduced nephrotoxic-
ity [22]. Furthermore, cationic surfactants and polymers
have an effect on integrity of red blood cells [28]. There-
fore, similar studies should be performed for the formula-
tions described in this paper.
Conclusion
Optimal colloid stability and maximal fungicidal activity
of monomeric or aggregated AmB in cationic lipid was
achieved for cationic formulations at low or high drug to
lipid molar proportions. At 0.005 mM drug, 1 mM
DODAB, 1 mg/mL CMC and ≥ 5 mg/mL PDDA, mono-
meric AmB was found in DODAB BF enveloped by the
two oppositely charged polyelectrolytes yielding 0% C.
albicans viability. At 0.05 mM drug, 0.1 mM DODAB, 0.1
Adsorption of carboxy methylcellulose onto amphotericin B-  cationic lipid assemblies preserves monomeric state of the  drug at the edges of cationic bilayer fragments Figure 3
Adsorption of carboxy methylcellulose onto ampho-
tericin B- cationic lipid assemblies preserves mono-
meric state of the drug at the edges of cationic 
bilayer fragments. Optical spectra of AmB in: 1:1 DMSO: 
methanol (best organic solvent mixture) (A); water (B); 
DODAB BF (C) or DODAB BF/AmB/CMC complexes (D). 
Final DODAB, AmB and/or CMC concentration are 1 mM, 
0.005 mM and 1 mg.mL-1, respectively.
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mg/mL CMC and PDDA ≥ 2 mg/mL, AmB/DODAB BF/
CMC/PDDA assembly contained AmB in the aggregated
state forming drug particles sequentially covered by
DODAB BF, CMC and PDDA yielding also 0% fungus via-
bility. The less tightly packed assembly turned out to be
the one at high P, and high drug concentration which eas-
ily delivered the drug to cells at the lower zeta-potentials.
The more tightly packed assembly was the one at low P,
delivering drug to cells at higher zeta-potentials and lower
drug concentration. In vitro both types of AmB formula-
tions yielded complete fungicidal effect against Candida
albicans (1 × 106 cfu/mL) representing good candidates to
further tests in vivo.
Methods
Drug, lipid, polyelectrolytes and microorganism
Dioctadecyldimethylammonium bromide (DODAB),
99.9% pure was obtained from Sigma Co. (St. Louis, MO,
USA). Carboxymethyl cellulose sodium salt (CMC) with a
nominal mean degree of substitution (DS) of 0.60–0.95,
poly(diallyldimethylammonium chloride) (PDDA) with
Mv 100,000–200,000 and polylysines (PL) were obtained
from Sigma (Steinheim, Germany) and used without fur-
ther purification. Amphotericin B (AmB, batch
008000336) was purchased from Bristol-Myers Squibb
(Brazil) and was initially prepared as a 1 g/L stock solu-
tion in DMSO/methanol 1:1. Candida albicans ATCC
90028 was purchased from American Type Culture Col-
lection (ATCC) and reactivated in Sabouraud liquid broth
4% before plating for incubation at 37°C/24 h. In order
to prepare fungal cell suspension for antifungal activity
assays, three to four colonies were picked from the plate
and washed twice either in isotonic glucose phosphate
buffer (IGP; 1 mM potassium phosphate buffer, pH 7.0,
supplemented with 287 mM glucose as an osmoprotect-
ant) [39,40] or in Milli-Q water by centrifugation (3000
rpm/10 minutes), pelleting and resuspension. The final
fungal cell suspension was prepared by adjusting the inoc-
ulum to 2 × 107 cfu/mL and then diluting by a factor of
Table 2: Sizing, zeta-potential and antifungal activity of drug, cationic lipid, and polyelectrolyte(s) assemblies
Cationic lipid, drug and polyelectrolyte assemblies D ± δ (nm) ζ ± δ (mV) Viability (%)
DODAB BF (0.6)/AmB (0.005)/CMC (1)/PDDA(1) 171 ± 1 24 ± 2 79 ± 5
DODAB BF (0.6)/AmB (0.005)/CMC (1)/PL5000–10000 (1) 92 ± 4 40 ± 1 71 ± 4
DODAB BF (0.6)/AmB (0.005)/CMC (1)/PL30000–70000 (1) 138 ± 5 50 ± 3 21 ± 9
DODAB BF (0.6)/AmB (0.005)/CMC (1)/PL70000–150000 (1) 148 ± 5 60 ± 3 13 ± 5
AmB (0.05)/DODAB BF (0.06)/CMC (0.1)/PDDA (1) 280 ± 2 35 ± 1 27 ± 2
AmB (0.05)/DODAB BF (0.06)/CMC (0.1)/PL5000–10000 (1) 238 ± 1 25 ± 7 37 ± 1
AmB (0.05)/DODAB BF (0.06)/CMC (0.1)/PL30000–70000 (1) 326 ± 5 36 ± 3 23 ± 6
AmB (0.05)/DODAB BF (0.06)/CMC (0.1)/PL70000–150000 (1) 417 ± 3 47 ± 5 11 ± 3
Zeta-average diameter (D) and zeta-potential (ζ) of novel cationic AmB formulations and their effect on C. albicans viability at low and high drug-to-
lipid molar proportions. Concentrations are given within parentheses in mg/mL. One should notice that polylysine (PL) with diferent molecular 
weights may alternatively replace PDDA and be used to control the positive zeta-potential of the outer layer.
Adsorption of poly(diallyldimethylammonium) chloride onto  carboxy methyl cellulose layer of amphotericin B- cationic  bilayer fragment Figure 4
Adsorption of poly(diallyldimethylammonium) chloride 
onto carboxy methyl cellulose layer of amphotericin B- 
cationic bilayer fragment. Effect of PDDA concentration on z-
average diameter (A) and zeta-potential (B) for DODAB BF/AmB/
CMC/PDDA assemblies. Final DODAB, AmB and CMC concen-
trations were 1 mM, 0.005 mM and 1 mg.mL-1, respectively. Inter-
action time between DODAB BF/AmB and CMC is 20 minutes. 
Thereafter, the interaction between DODAB BF/AmB/CMC and 
PDDA lasted 30 minutes.
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1:10 either in IGP or in Milli-Q water yielding 2 × 106 cfu/
mL.
Preparation of lipid dispersion and analytical 
determination of lipid concentration
DODAB was dispersed in water or IGP buffer, using a tita-
nium macrotip probe [41]. The macrotip probe was pow-
ered by ultrasound at a nominal output of 90 W (10
minutes, 70°C) to disperse 32 mg of DODAB powder in
25 mL water solution. The dispersion was centrifuged (60
minutes, 10000 g, 4°C) in order to eliminate residual tita-
nium ejected from the macrotip. This procedure dispersed
the amphiphile powder in aqueous solution using a high-
energy input, which not only produced bilayer vesicles
but also disrupted these vesicles, thereby generating open
BF [29,41]. Analytical concentration of DODAB was
determined by halide microtitration [42] and adjusted to
2 mM.
Determination of zeta-average diameter and zeta-
potential for dispersions
Stock solutions of AmB were prepared at 1 mg/mL in 1:1
DMSO/methanol. Stock solutions of PDDA, CMC and PL
were prepared at 20 mg/mL and diluted in the final dis-
persion to yield the desired final concentration. The stock
solution of AmB (1 mg/mL) was added to DODAB BF dis-
persions to yield low and high drug to lipid molar propor-
tions (P). At low P, dispersions contained final
concentrations of drug, DODAB, CMC and PDDA equal
to 0.005 mM (5 micrograms/mL), 1 mM (631 micro-
grams/mL), 0.01–2.00 mg/mL and 0.01–10.00 mg/mL,
respectively. Firstly, DODAB BF and drug were allowed to
interact for 10 minutes. Thereafter, CMC was added and
allowed to interact for 20 minutes before adding PDDA,
which was also allowed to interact for 20 minutes, before
determining zeta-average diameter and zeta-potentials. At
high P, a similar procedure was done this time at final
concentrations of drug, DODAB, CMC and PDDA equal
to 0.050 mM (50 micrograms/mL), 0.1 mM (63.1 micro-
Fungicidal activity of different assemblies at low P against fungus Figure 5
Fungicidal activity of different assemblies at low P against fungus. Cell viability (%) of Candida albicans (1 × 106 cfu/mL) 
as a function of polyelectrolytes concentration. Cells and CMC (A); DODAB/AmB/CMC (B); CMC/PDDA (C) and DODAB/
AmB/CMC/PDDA (D) interacted for 1 h before dilution and plating on agar of 0.1 mL of the diluted mixture (1:1000 dilution).Journal of Nanobiotechnology 2008, 6:6 http://www.jnanobiotechnology.com/content/6/1/6
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grams/mL), 0.01–2.00 mg/mL and 0.01–10.00 mg/mL,
respectively. At high P, drug particles were obtained at
0.050 mM AmB in IGP buffer yielding particles with 75
nm zeta-average diameter and -27 mV zeta-potential [35].
These drug particles were firstly covered by DODAB BF
and then wrapped by the polyelectrolytes over the quoted
range of concentrations. Sizes and zeta-potentials were
determined by means of a ZetaPlus Zeta-Potential Ana-
lyser (Brookhaven Instruments Corporation, Holtsville,
NY, USA) equipped with a 570 nm laser and dynamic
light scattering at 90° for particle sizing [43]. The zeta-
average diameters referred to in this work from now on
should be understood as the mean hydrodynamic diame-
ters Dz. Zeta-potentials (ζ) were determined from the elec-
trophoretic mobility µ and Smoluchowski's equation, ζ =
µη/ε, where η and ε are medium viscosity and dielectric
constant, respectively. All Dz and ζ were obtained at 25°C,
1 h after mixing.
Optical spectra and aggregation state of AmB in the 
formulations
UV-visible optical spectra (280–450 nm) for characteriza-
tion of AmB aggregation state were obtained in the dou-
ble-beam mode by means of a Hitachi U-2000
Spectrophotometer against a blank of DODAB BF or
DODAB BF/CMC (without drug), to separate light scat-
tered by the dispersions from light absorption by the drug.
All spectra were obtained at room temperature (25°C) at
about 20 minutes after mixing DODAB BF and AmB at
low or high drug to lipid P or after adding CMC to
DODAB BF/drug assemblies.
Amphotericin B aggregates covered by a layer of cationic lipid adsorb a layer of carboxymethyl cellulose Figure 6
Amphotericin B aggregates covered by a layer of cationic lipid adsorb a layer of carboxymethyl cellulose. Effect 
of CMC concentration on zeta-average diameter (A, C) and zeta-potential (B, D) of DODAB BF (A, B) or AmB/DODAB BF 
(C, D) at high P. Final DODAB and/or AmB concentrations were 0.1 and 0.05 mM, respectively. The three different moieties of 
the curves were named I, II and III corresponding to positive, zero and negative zeta-potentials, respectively. Interactions 
DODAB BF/CMC or AmB/DODAB BF/CMC took place over 20 minutes before measurements. One should notice that, at 
high P, [DODAB] concentration is 20 times smaller than at low P (Figure 1) surrounding drug aggregates as a thin layer of cat-
ionic lipid. 34
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Determination of cell viability for C. albicans ATCC 90028 
as a function of polyelectrolytes concentration at low and 
high drug to lipid molar proportion (P)
At low or high P, DODAB/drug assemblies were wrapped
by two layers of oppositely charged polyelectrolytes so
that cfu were counted as a function of CMC and/or PDDA
concentrations at 1 h of interaction time between C. albi-
cans (1 × 106 cfu/mL) and formulations. Plating on agar
plates for cfu counts was performed by taking 0.1 mL of a
1000-fold dilution in Milli-Q water of the mixtures. After
spreading, plates were incubated for 2 days at 37°C. CFU
counts were made using a colony counter. At low P, final
DMSO/methanol concentration is 0.5% whereas at high P
it is 5%. No effect of the solvent mixture at 0.5% on cells
viability was previously detected [25]. For further studies
in vivo and at high P, it will be advisable to perform a dial-
ysis step for the cationic nanoparticles aiming at complete
elimination of the toxic solvent mixture.
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Amphotericin B particles covered by a thin layer of cationic  lipid, at high P, and surrounded by a layer of carboxymethyl  cellulose further adsorb a layer of cationic polyelectrolyte Figure 8
Amphotericin B particles covered by a thin layer of 
cationic lipid, at high P, and surrounded by a layer of 
carboxymethyl cellulose further adsorb a layer of 
cationic polyelectrolyte. Effect of PDDA concentration 
on zeta-average diameter (A) and zeta-potential (B) for AmB/
DODAB BF/CMC/PDDA complexes. Final DODAB, AmB 
and CMC concentrations were 0.1 mM, 0.05 mM and 0.1 g.L-
1, respectively. Interactions DODAB BF/AmB and CMC took 
place over 20 minutes and AmB/DODAB BF/CMC and 
PDDA, over 30 minutes.
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Amphotericin B is found as in the aggregated state (drug par- ticles) covered by a thin layer of cationic lipid further sur- rounded by a layer of carboxymethyl cellulose at high P Figure 7
Amphotericin B is found as in the aggregated state 
(drug particles) covered by a thin layer of cationic 
lipid further surrounded by a layer of carboxymethyl 
cellulose at high P. Optical spectra of AmB in isotonic glu-
cose buffer (A); AmB/DODAB BF (B) or AmB/DODAB/
CMC complexes (C). Final DODAB, AmB and/or CMC con-
centration were 0.1 mM, 0.05 mM e 0.1 mg.mL-1, respec-
tively. These conditions yield complexes at high P.
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Fungicidal activity of different assemblies at high P against fungus Figure 9
Fungicidal activity of different assemblies at high P against fungus. Cell viability (%) of Candida albicans (1 × 106 cfu/
mL) as a function of CMC (A, B) or PDDA (C, D) concentration in the presence of different assemblies: CMC only (A); AmB/
DODAB/CMC (B); CMC/PDDA (C) and AmB/DODAB/CMC/PDDA (D). The assemblies interacted with cells for 1 h before 
dilution (1:1000) and plating on agar of 0.1 mL of the diluted mixture.
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